Evommune, Inc./$EVMN
1D1W1MYTD1Y5YMAX
Capital at risk
About Evommune, Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
- Ticker
- $EVMN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 48
- Headquarters
- Palo Alto, United States
- Website
- www.evommune.com
Evommune, Inc. Metrics
BasicAdvanced
$340M
-
-$4.15
-
-
Price and volume
Market cap
$340M
52-week high
$33.20
52-week low
$9.30
Average daily volume
577K
Financial strength
Current ratio
11.68
Quick ratio
11.482
Long term debt to equity
0.025
Total debt to equity
0.031
Profitability
EBITDA (TTM)
-100.356
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-946.68%
Operating margin (TTM)
-1,018.94%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-31.99%
Return on equity (TTM)
-52.11%
Valuation
Price to revenue (TTM)
21.384
Price to book
1.22
Price to tangible book (TTM)
1.22
Price to free cash flow (TTM)
-2.864
Free cash flow yield (TTM)
-34.91%
Free cash flow per share (TTM)
-3.271
Growth
Revenue change (TTM)
233.33%
Earnings per share change (TTM)
-90.41%
What the Analysts think about Evommune, Inc.
Analyst ratings (Buy, Hold, Sell) for Evommune, Inc. stock.
Analyst projections of the future price of Evommune, Inc. stock.
Bulls say / Bears say
EVO301 delivered positive Phase 2a proof-of-concept data in atopic dermatitis, providing a clinical read-through for its IL-18BP fusion-protein mechanism and becoming Evommune’s lead AD program after EVO756’s failure. (Evommune)
Evommune reported $288.0 million of cash, cash equivalents and investments as of June 30, 2026, and said its balance sheet supports operations into 2029, providing substantial funding for upcoming clinical milestones without an immediate financing requirement. (Evommune)
Despite the AD and CSU setbacks, EVO756 remains in a global Phase 2b migraine-prophylaxis trial enrolling approximately 330 patients, with top-line data expected in 2027; its generally well-tolerated safety profile preserves potential value in a new indication. (Evommune)
EVO756 failed to meet both primary and secondary endpoints in its 121-patient Phase 2b atopic-dermatitis trial, and Evommune will not advance the program in AD. (Evommune)
EVO756 also failed its Phase 2b trial in chronic spontaneous urticaria, leading Evommune to discontinue development in that indication and reducing the asset’s near-term commercial opportunity. (Evommune)
Evommune remains pre-commercial, reporting zero revenue in the second quarter of 2026 and a $32.2 million quarterly net loss; continued development therefore depends on its cash balance and future financing or partnering. (Evommune)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Evommune, Inc. Financial Performance
Revenues and expenses
Evommune, Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Evommune, Inc. News
AllArticlesVideos
Funds containing Evommune, Inc.
Fund name | Fund size | $EVMN weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.